HOUSTON, July 31, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that its Clinigence Health advanced population health analytics platform has been selected by Varmed Management, a Puerto Rico-based medical management company, to enhance its population health capabilities and patient care.
Clinigence Health's partnership with Varmed Management honors the company's commitment to improving quality of life and health outcomes through implementing advanced analytics and cutting-edge technology. Together, they aim to deliver unparalleled solutions to patients, ensuring seamless, whole-person care while reducing costs.
Clinigence Health is thrilled to assist Varmed Management in its mission. Sophisticated population health management requires a platform like Clinigence Health that helps organizations enhance the care delivered to their patients by identifying opportunities to engage its physicians and its patients with data to drive continued quality improvement.
"The partnership creates an environment where high-quality care is accessible and affordable to everyone in our community. By integrating Clinigence Health's advanced analytics into our population health management strategy, we can provide even more personalized patient care," stated José J. Vargas, Chief Executive Officer of Varmed Management.
"The healthcare industry continues to experience the loss of billions of premium dollars to overutilization and inappropriate use of services to the detriment of patient care. The transition to value-based care models requires organizations to understand the patterns of care and best medical practices that allow quality care to be delivered cost-effectively," stated Lawrence Schimmel, M.D., Chief Medical Information Officer of Nutex Health, Inc.
"Clinigence is a pioneer in clinical data integration, clinical quality reporting and population health analytics. Our scalable, purpose-built cloud-based platform has clinical and claims data on over 3 million patients and is in use by multiple independent practice associations ("IPAs"), medical groups, accountable care organizations ("ACOs"), hospitals and physicians. We look forward to partnering with the talented team at Varmed," stated Warren Hosseinion, M.D., President of Nutex Health.
For more information, visit Clinigence Health at www.clinigencehealth.com or email This email address is being protected from spambots. You need JavaScript enabled to view it. for personalized information requests.
About Nutex Health Inc.
Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in 8 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.
About Varmed Management
Varmed Management is a fully integrated healthcare solutions provider. As a population health management organization, we are committed to providing cutting-edge solutions to our clients, improving quality of life through patient empowerment, improving healthcare outcomes and reducing costs. www.varmedmanagement.com
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended March 31, 2023 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Last Trade: | US$30.28 |
Daily Change: | -1.49 -4.69 |
Daily Volume: | 7,696 |
Market Cap: | US$164.720M |
November 07, 2024 August 08, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB